冠昊生物 reported revenue of ¥0.17B for the period ended 2026-06-30, -13.1% year on year. Net income was ¥0.01B, a 4.4% net margin on a 76.2% gross margin. The largest revenue line is 医疗器械 at 75% of the total. Free cash flow for the period was ¥0.00B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.17B | -13.1% |
| Gross profit | ¥0.13B | — |
| Operating income | ¥0.01B | — |
| Net income | ¥0.01B | -53.6% |
| Gross margin | 76.2% | Net margin 4.4% |
| Revenue Q/Q | -13.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| 医疗器械 | ¥0.13B | 74.8% |
| 药品 | ¥0.03B | 14.9% |
| 租赁及其他服务业 | ¥0.02B | 10.3% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.04B | 23.8% |
| R&D | ¥0.02B | 9.2% |
| SG&A | ¥0.10B | 57.1% |
| Tax & other | ¥0.01B | 3.1% |
| Item | Amount |
|---|---|
| Total assets | ¥0.78B |
| Total liabilities | ¥0.28B |
| Shareholders' equity | ¥0.50B |
| Equity / assets | 63.5% |
| Operating cash flow | ¥0.01B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥0.00B |
| Cash conversion (OCF / net income) | -88% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
东宝生物 ・ 飞力达 ・ 瑞丰光电 ・ 佳云科技 ・ 瑞丰高材 ・ 迪安诊断 ・ ST天玑 ・ 宝莱特 ・ 融捷健康 ・ 新开普 ・ 依米康 ・ 初灵信息
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies